Update on the phased implementation of myeloid malignancy and chronic lymphocytic leukaemia to the Trusight Oncology 500
From September 2nd AWMGS is pleased to announce all referrals for myeloid malignancy and chronic lymphocytic leukaemia will now be sequenced using the Trusight Oncology 500. While the changes do not affect current reporting, the perceived benefits realisation associated with the transition include:
- Variant allele frequency - Improved efficiency across the laboratory - Reduced turnaround times - Haematological aligning to the NHSE Test Directory to ensure Welsh patients have the parity of access regardless of their geographical location
The Trusight 500 is also anticipated to future proof cancer genomic testing in Wales and allow the laboratory to be more responsive to new published guidance and subsequent recommendations.
